Migraine Treatment: From Symptomatic Relief to Targeted Therapy...

On March 31st, the latest announcement on the website of the Center for Drug Evaluation (CDE) revealed that the marketing application for Pfizer‘s Rimegepant Sulfate Orally Disintegratin...

See More

A Deep Dive into the Quality Cornerstone of GLP-1 drug...

GLP-1 receptor agonist drugs, represented by semaglutide and tirzepatide, have faced intensified scrutiny and warnings from regulatory agencies worldwide....

See More

FDA Approves Wegovy® Pill, Ushering in a New Era of Oral Obesity Tr...

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Wegovy® tablets (containing 25 mg of semaglutide for once-daily oral administration) to help reduce exc...

See More

world first！A New Treatment Option for DPNP and the Critical Control ...

Recently, the Lidocaine Gel Patch (brand name: DeBaiNing®), developed by Tide Pharm, a subsidiary of China Biopharmaceuticals, has been granted approval for a new indication by the Nation...

See More

Diverse Options in Influenza Prevention and Control: How to Ensure Drug ...

As the flu season persists, drug quality control becomes a critical link in ensuring public medication safety. Drug impurity reference standards, serving as the "benchmark" in drug quality research,...

See More

Combination Nasal Spray Ryaltris® Disrupts the Rhinitis Market: How We...

On November 10th, the compound nasal spray containing Olopatadine Hydrochloride and Mometasone Furoate (brand name: Ryaltris®), jointly developed by Grand Pharmaceutical Group‘s subsidiary...

See More

China’s First Domestically Developed Dulaglutide Injection Approved for ...

On August 8, Boan Biotechnology announced that its independently developed Boyouping® (Dulaglutide Injection) has received market approval from the National Medical Products Administration...

See More

Qilu Pharmaceutical Co.,Ltd.’s Carfilzomib for Injection Approved for M...

Qilu Pharmaceutical Co.,Ltd’s Carfilzomib for Injection has received market approval from the National Medical Products Administration (NMPA) of China for the treatment of adult patie...

See More

First-in-Class: FDA OKs Triple Therapy to Treat Hypertension...

Recently, George Medicines announced that its new drug Widaplik® (containing telmisartan, amlodipine, and indapamide, previously known as GMRx2) has been approved by the U.S. Food and Drug...

See More

LEQEMBI IQLIK™, the first-ever at-home subcutaneous injection for A...

The U.S. FDA has approved the lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI IQLIK™), jointly developed by Biogen and Eisai, for maintenance therapy in early A...

See More

​​Breaking Dosage Form Barriers: Escitalopram Oxalate Drops Approval ...

the Escitalopram Oxalate Drops of Guangzhou Yipinhong Pharmaceutical Co., Ltd successfully obtained the drug registration certificate issued by the National Medical Products Administration...

See More

the first approval of an oro-dispersible film dosage form in China...

Qilu Pharmaceutical’s risperidone oro-dispersible film has been formally approved for market launch by the National Medical Products Administration (NMPA), marking the first approval of an ...

See More

​​J&J Submits Oral IL-23 Peptide Drug for FDA Approval: Sustained...

Global pharmaceutical giant Johnson & Johnson (J&J) and Protagonist Therapeutics recently announced the formal submission of a New Drug Application (NDA) to the U.S. Food and Drug Ad...

See More

Seloxavir Marboxil Tablets Approved: The Quality Control System Behind ...

On July 18, the domestic self-developed anti-influenza oral drug Seloxavir Marboxil Tablets has been officially approved by China‘s National Medical Products Administration (NMPA) for ...

See More

​​Mazdutide — World‘s First GCG/GLP-1 Dual-Receptor Agonist for ...

On June 27, Innovent Biologics’ Mazdutide Injection received approval from China‘s National Medical Products Administration (NMPA) for long-term weight control in adults with obesity ...

See More

​​Consistency Evaluation of Generic Drugs: June 2025 Update...

In June 2025, a total of 27 varieties (39 acceptance numbers) submitted applications for consistency evaluation, 30 varieties of consistency evaluation over-evaluation, 245 deemed to have passed con...

See More

Groundbreaking COPD Therapy: CTTQ PHARMA‘S TQC3721 Suspens...

CTTQ PHARMA recently announced that its inhaled PDE3/4 dual inhibitor ​​TQC3721 suspension​​ has received approval from China’s Center for Drug Evaluation (CDE) to initiate...

See More

Enhanced Supervision in Pharmaceutical Regulation​​...

Pharmaceutical companies must urgently implement such as stringenting raw material controls ,Enhancing process validation protocols and advancing trace-level detection capabilities for emerging carc...

See More

AstraZeneca‘s AKT Inhibitor Capivasertib Gains Domestic Approval, Re...

The domestic launch of capivasertib propels targeted therapy advancements while necessitating more rigorous standards in multiple domains: exploration of CDK4/6 inhibitor resistance mechanisms, im...

See More

The 2025 Edition of the Chinese Pharmacopoeia is Officially Released!...

Recently, the Pharmacopoeia of China (2025 Edition) was officially released. As the core of the national drug standard system, the new edition of the Pharmacopoeia realizes a number of breakthro...

See More